FrancophonIA/ELRC3.0 huggingface dataset:
English: For cabergoline and pergolide, the Committee noted that the risk of fibrosis of the heart valves is well established, that the prescribing information for both products already includes contraindications stating that patients with evidence of heart valve problems should not take them, and that the medicines should only be used for Parkinson's disease in patients who have already taken or cannot take other treatments.
Estonian: Komitee täheldas, et kabergoliini ja pergoliidi korral on südameklappide fibroosi risk hästi teada, kummagi toote väljakirjutamiseks kasutatav teave juba sisaldab vastunäidustusi ja hoiatust, et südameklapiprobleemidega patsiendid ei tohi neid manustada, ning et ravimeid tuleb kasutada Parkinsoni tõve raviks üksnes nendel patsientidel, kes on juba saanud või kellele ei saa määrata muud ravi.
English: Ergot-derived dopamine agonists are a group of medicines consisting of bromocriptine, cabergoline, dihydroergocryptine, lisuride and pergolide.
Estonian: Tungaltera derivaadid dopamiini agonistid on ravimite rühm, kuhu kuuluvad bromokriptiin, kabergoliin, dihüdroergokrüptiin, lisuriid ja pergoliid.
English: They are also used to treat conditions including hyperprolactinaemia (high levels of the hormone prolactin in the blood) and prolactinoma (a non-cancerous tumour of the pituitary gland at the base of the brain), and to prevent lactation (production of breast milk) and migraine.
Estonian: Neid kasutatakse samuti selliste haigusseisundite nagu hüperprolaktineemia (hormoon prolaktiini suur sisaldus veres) ja prolaktinoomi (aju alumisel pinnal asuva ajuripatsi healoomulise kasvaja) raviks ning laktatsiooni (rinnapiima eritumise) ja migreeni ennetamiseks.
English: Therefore, the CHMP recommended that the prescribing information for these two medicines should be updated to include:
Estonian: Seetõttu soovitas inimravimite komitee ajakohastada nende kahe ravimi väljakirjutamiseks kasutatavat teavet, täiendades seda järgmise teabega:
English: They have been available on the market for many years and are mainly used to treat Parkinson's disease, either on their own or in combination with other medicines.
Estonian: Neid ravimeid on turustatud juba palju aastaid ning neid kasutatakse kas iseseisvalt või koos teiste ravimitega peamiselt Parkinsoni tõve raviks.
English: The CHMP also recommended that companies that make these two medicines should conduct studies to look at how closely doctors follow the updated prescribing information and the impact that these changes have on the incidence of fibrosis of the heart valves.
Estonian: Samuti soovitas inimravimite komitee neid kahte ravimit tootvatel ettevõtetel korraldada uuringud, milles vaadeldakse, kui täpselt järgivad arstid väljakirjutamiseks kasutatavat ajakohastatud teavet ning milline on muudatuste mõju südameklappide fibroosi esinemissagedusele.
English: • Patients should be monitored for the signs of fibrosis in the heart and elsewhere in the body throughout treatment, using blood tests or chest X-rays as appropriate.
Estonian: • Patsiente tuleb kogu ravi kestel jälgida, kas südames ja mujal organismis esinevad fibroosi sümptomid, kasutades vajaduse korral vereanalüüse või rindkere röntgeniülesvõtteid.
English: • Ergot-derived dopamine agonists should not be taken by patients who have had fibrosis in the heart, lungs or abdomen.
Estonian: • Tungaltera derivaate dopamiini agoniste ei tohi manustada patsiendid, kellel on esinenud südame-, kopsu- või kõhufibroos.
English: The CHMP reviewed all of the available information on the risk of fibrosis and valve problems from clinical trials, observational studies (studies looking at the effects of medicines as they are used by patients) and ‘spontaneous reports' of side effects made by patients or doctors to the companies that make the medicines or to health authorities.
Estonian: Inimravimite komitee vaatas läbi kõik fibroosiriski ja südameklappide probleeme käsitlevad kättesaadavad andmed, mis pärinesid kliinilistest uuringutest, vaatlusuuringutest (uuringud, milles vaadeldakse patsientide poolt kasutatavate ravimite mõju) ja kõrvalnähtusid kirjeldavatest omaalgatuslikest teadetest, mille patsiendid või arstid olid saatnud ravimeid tootvatele ettevõtetele või tervishoiuasutustele.
English: • ‘cardiac fibrosis' as a ‘very common' side effect (seen in more than 1 patient in 10 taking either medicine).
Estonian: • südamefibroosi esinemine väga sagedase kõrvalnähuna (esinenud enam kui ühel ükskõik kumba ravimit võtval patsiendil kümnest).
English: Based on the information available, the CHMP has concluded that the marketing authorisations for the ergot-derived dopamine agonists should be maintained, but changes to the prescribing information for the medicines should be introduced to reduce the risk of fibrosis.
Estonian: Kättesaadavate andmete põhjal jõudis inimravimite komitee järeldusele, et tungaltera derivaatide dopamiini agonistide müügiload tuleb alles jätta, kuid ravimite väljakirjutamiseks kasutatavat teavet tuleb muuta, et vähendada fibroosiriski.
English: Among the ergot-derived dopamine agonists, cabergoline and pergolide activate these receptors most strongly, possibly explaining the greater risk of fibrosis seen with these medicines.
Estonian: Tungaltera derivaatidest dopamiini agonistidest aktiveerivad kabergoliin ja pergoliid neid retseptoreid kõige tugevamalt, mis võib seletada nende ravimite korral täheldatud suuremat fibroosiriski.
English: The European Medicines Agency (EMEA) has completed a review of the safety of the ergot-derived dopamine agonists, a group of medicines that are mainly used to treat Parkinson's disease.
Estonian: Euroopa Ravimiamet (EMEA) on lõpetanud tungaltera derivaatide dopamiini agonistide - peamiselt Parkinsoni tõve raviks kasutatavate ravimite rühma - ohutuse läbivaatamise.
English: What are ergot-derived dopamine agonists?
Estonian: Mis on tungaltera derivaadid dopamiini agonistid?
English: The review focused on the risk of fibrosis (the formation of fibrous tissue in some body structures) in patients taking these medicines for long periods, particularly cardiac fibrosis (abnormal thickening of the heart valves).
Estonian: Läbivaatamisel keskenduti fibroosi (organismi teatavates struktuurides fibrooskoe tekkimise), eelkõige südamefibroosi (südameklappide ebanormaalne paksenemine) riskile patsientidel, kes võtavad neid ravimeid pika aja vältel.
English: In contrast, there is not enough evidence to determine whether there is an increased risk of fibrosis of the heart valves in patients taking bromocriptine, dihydroergocryptine or lisuride.
Estonian: Seevastu puuduvad piisavad andmed selle kohta, kas bromokriptiini, dihüdroergokrüptiini või lisuriidi manustavatel patsientidel on südameklappide fibroosi risk suurenenud.
English: This group of dopamine agonists are called ‘ergotderived', because they were first produced from a type of fungus called ergot.
Estonian: Selle rühma dopamiini agoniste nimetatakse tungaltera derivaatideks, sest esialgu toodeti neid parasiitseenest tungalterast.
English: Consequently, the United Kingdom's medicines regulatory authority asked the CHMP to review the risk of fibrosis, including cardiac fibrosis, associated with the use of ergot-derived dopamine agonists.
Estonian: Seepärast palus Ühendkuningriigi ravimiamet inimravimite komiteel hinnata tungaltera derivaatide dopamiini agonistide kasutamisega seotud fibroosi, sealhulgas südamefibroosi riski.
English: However, since such a risk cannot completely be excluded, the Committee recommended that warnings on the possible risk of fibrosis in patients taking these medicines at high doses for long periods should be included in their prescribing information.
Estonian: Et seda riski ei saa siiski täielikult välistada, soovitas komitee ravimite väljakirjutamise teavet täiendada hoiatusega võimaliku fibroosiriski kohta patsientidel, kes manustavad neid ravimeid suurtes annustes pika aja jooksul, ning kehtestada bromokriptiini annuse ülempiiriks 30 mg päevas.
English: The development of the symptoms of fibrosis has been known as a side effect of ergot-derived dopamine agonists for many years, particularly when the medicines are used for long periods.
Estonian: Tungaltera derivaatide dopamiini agonistide kõrvalnähu fibroosi sümptomite väljakujunemisest, eriti ravimite pikaajalise kasutamise korral, ollakse juba palju aastaid teadlikud.
English: The absence of fibrosis in the heart should be verified before treatment is started.
Estonian: Enne ravi alustamist tuleb südant fibroosi suhtes uurida.
English: • Doctors should prescribe ergot-derived dopamine agonists according to the updated prescribing information.
Estonian: • Arstid peavad tungaltera derivaatide dopamiini agonistide väljakirjutamisel lähtuma ajakohastatud teabest.
English: QUESTIONS AND ANSWERS ON THE REVIEW OF ERGOT-DERIVED DOPAMINE AGONISTS
Estonian: TEAVE TUNGALTERA DERIVAATIDE DOPAMIINI AGONISTIDE LÄBIVAATAMISE KOHTA
English: Why have ergot-derived dopamine agonists been reviewed?
Estonian: Mis oli tungaltera derivaatide dopamiini agonistide läbivaatamise põhjus?
English: Dopamine agonists work by stimulating brain and nerve cells in a similar way to dopamine, a messenger substance in the nervous system.
Estonian: Dopamiini agonistide tööpõhimõte on sarnaselt närvisüsteemi vahendusaine dopamiiniga stimuleerida ajurakke ja närvirakke.
English: In addition, the CHMP recommended that a contraindication for patients with pre-existing valve problems should be included in the prescribing information for bromocriptine and dihydroergocryptine-containing medicines.
Estonian: Peale selle soovitas inimravimite komitee täiendada bromokriptiini ja dihüdroergokrüptiini sisaldavate ravimite väljakirjutamiseks kasutatavat teavet vastunäidustusega nendele patsientidele, kellel juba esineb südameklapiprobleeme.
English: --1 ≥ 394AU/ml (Antigenic units determined by ELISA) (1400 AU corresponding to ≥ 492 AU in the potency test)
Estonian: --1 ≥ 394AÜ/ml (antigeenset ühikut, mis on määratud ELISA meetodil) (1400 AÜ vastab ≥ 492 AÜ-le tõhususuuringus)
English: 10 vials Zero days
Estonian: 10 viaali 0 päeva
English: Vial (type I glass) closed with a rubber stopper secured with aluminium cap
Estonian: Viaal (I tüübi klaas) suletud kummikorgiga ja kaitstud alumiiniumkattega
English: Packaging Content Package size
Estonian: Sisaldus Pakend i suurus
English: The withdrawal letter is available here.
Estonian: Tagasivõtmise kiri on siin.
English: 14 December 2012 EMA/807998/2012 EMEA/H/C/2259
Estonian: EMEA/H/C/2259
English: What is Jenzyl?
Estonian: Mis on Jenzyl?
English: It was to be available as 10 mg tablets.
Estonian: Ridaforoliimust kavatseti turustada 10 mg tablettidena.
English: The company had not yet responded to the last round of questions at the time of the withdrawal.
Estonian: Ettevõte ei olnud taotluse tagasivõtmise ajaks viimastele küsimustele veel vastanud.
English: The CHMP considered this benefit to be modest, when taking into account that patients usually survived for a long time after their disease had progressed.
Estonian: Inimravimite komitee arvates oli see kasu mõõdukas, kui arvestada asjaolu, et tavaliselt elasid patsiendid pärast haiguse progresseerumist küllalt kaua.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Jenzyl can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (soft tissue sarcoma and primary malignant bone tumours).
Estonian: Harvikravimite komitee arvamuse kokkuvõte Jenzyli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (soft tissue sarcoma, primary malignant bone tumours).
English: The main measure of effectiveness was the time patients lived until their disease got worse.
Estonian: Efektiivsuse põhinäitaja oli aeg patsientide haiguse halvenemiseni.
English: The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated a list of questions.
Estonian: Taotlus võeti tagasi pärast seda, kui inimravimite komitee oli hinnanud ettevõtte esitatud dokumente ja koostanud ettevõttele vastamiseks küsimused.
English: This is expected to slow down the growth and proliferation of cancer cells.
Estonian: Arvatakse, et see aeglustab vähirakkude kasvu ja vohamist.
English: Withdrawal of the marketing authorisation application for Jenzyl (ridaforolimus)
Estonian: Müügiloa taotluse tagasivõtmise teave Jenzyl (ridaforoliimus)
English: Since mTOR is involved in the control of cell division and the growth of blood vessels, ridaforolimus prevents the division of tumour cells and reduces their blood supply.
Estonian: Et mTOR reguleerib rakkude jagunemist ja veresoonte kasvu, hoiab ridaforoliimus ära kasvajarakkude jagunemise ning vähendab nende verevarustust.
English: Jenzyl is a medicine that contains the active substance ridaforolimus.
Estonian: Jenzyl on ravim, mis sisaldab toimeainena ridaforoliimust.
English: In terms of safety, the CHMP was concerned by the high frequency of side effects interfering with the patient's wellbeing as well as some uncommon but potentially lifethreatening side effects.
Estonian: Ohutuse osas tegi inimravimite komiteed ettevaatlikuks patsientide heaolu mõjutavate kõrvalnähtude suur esinemissagedus ja samuti mõned aeg-ajalt esinevad, ent potentsiaalselt eluohtlikud kõrvalnähud.
English: The study compared Jenzyl with placebo (a dummy treatment).
Estonian: Uuringus võrreldi Jenzylit platseeboga (näiv ravim).
English: The CHMP also considered that the somewhat larger effect seen in patients who had received two or three previous regimens of chemotherapy compared with those who received one or more regimens might not reflect the medicine's true effect size, as the reason the medicine would work better at later stages of the disease was unclear.
Estonian: Inimravimite komitee leidis samuti, et mõnevõrra tugevam toime, mida täheldati patsientidel, kes olid varem saanud ravi kahe või kolme keemiaraviskeemi järgi, võrreldes vähemalt ühe keemiaraviskeemi järgi ravi saanud patsientidel esinenud toimega, ei pruugi näidata ravimi tegelikku toime tugevust, sest ei ole selge, miks peaks ravim haiguse hilisemates staadiumites paremini toimima.
English: The company presented the results of one main study involving 711 patients with metastatic soft tissue sarcoma or bone sarcoma who have received up to four cycles of one, two or three alternative chemotherapy regimens.
Estonian: Ettevõte esitas ühe põhiuuringu tulemused, milles osales 711 pehmekudede metastaatilise sarkoomi või luusarkoomiga patsienti, kes olid varem saanud ravi neli tsüklit ühe, kahe või kolme alternatiivse keemiaraviskeemi järgi.
English: It was expected to be used as maintenance therapy in patients who have already received two or three regimens of chemotherapy.
Estonian: Jenzylit kavatseti kasutada säilitusravina patsientidel, kes on juba saanud ravi kahe või kolme keemiaraviskeemi järgi.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Jenzyl did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et Jenzyli kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: The CHMP was concerned that taking Jenzyl only led to a small increase in the time patients lived until their disease got worse compared with placebo (18 versus 15 weeks in patients who had one or more regimens of previous chemotherapy, and 16 versus 10 weeks in patients who had received two or three previous regimens of chemotherapy).
Estonian: Inimravimite komiteed tegi ettevaatlikus asjaolu, et Jenzyli kasutamisel elasid patsiendid platseeboga võrreldes ainult veidi kauem, enne kui nende haigus halvenes (vastavalt 18 nädalat vs 15 nädalat, kui patsiendid olid varem saanud ravi vähemalt ühe keemiaraviskeemi järgi, ja 16 nädalat vs 10 nädalat, kui patsiendid olid varem saanud ravi kahe või kolme keemiaraviskeemi järgi).
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it decided to withdraw the application since the CHMP considered that the data provided did not allow the Committee to conclude on a positive benefit-risk balance.
Estonian: Oma kirjas, milles ettevõte teatas Euroopa Ravimiametile taotluse tagasivõtmisest, märgiti taotluse tagasivõtmise põhjusena seda, et inimravimite komitee arvates ei tõendanud esitatud andmed ravimi positiivset kasulikkuse ja riski tasakaalu.
English: What was Jenzyl expected to be used for?
Estonian: Milleks kavatseti Jenzylit kasutada?
English: How is Jenzyl expected to work?
Estonian: Milline on Jenzyli eeldatav toime?
English: Jenzyl was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 26 August 2005 and 28 October 2005 for the treatment of soft tissue sarcoma and primary malignant bone tumours.
Estonian: Jenzyl nimetati 26. augustil 2005 pehmekudede sarkoomi ja 28. oktoobril 2005 esmaste pahaloomuliste luukasvajate ravi näidustustel harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Jenzyl could not have been approved for the treatment of patients with metastatic soft tissue sarcoma or bone sarcoma as maintenance therapy.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks, ja oli esialgsel seisukohal, et Jenzyli kasutamist pehmekudede metastaatilise sarkoomi või luusarkoomiga patsientide säilitusraviks ei ole võimalik heaks kiita.
English: What consequences does this withdrawal have for patients in clinical trials?
Estonian: Kuidas mõjutab tagasivõtmine praegu kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials using Jenzyl.
Estonian: Taotluse tagasivõtmine ei mõjuta praegu Jenzyli kliinilistes uuringutes osalevaid patsiente.
English: On 27 November 2012, Merck Sharp & Dohme Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Jenzyl, for the maintenance treatment of patients with metastatic soft tissue sarcoma or bone sarcoma previously treated with chemotherapy.
Estonian: Merck Sharp & Dohme Limited teatas 27. novembril 2012 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Jenzyl müügiloa taotlus.
English: Jenzyl was expected to be used for the treatment of adults with soft tissue sarcoma (a type of cancer that affects the soft, supporting tissues of the body) or bone sarcoma (bone cancer) that are metastatic (have spread to other parts of the body).
Estonian: Jenzylit kavatseti kasutada pehmekudede metastaatilise (teistesse kehapiirkondadesse levinud) sarkoomi (kasvaja liik, mis tabab organismi pehmekudesid ehk tugikudesid) või luusarkoomiga (luukasvaja) täiskasvanud patsientide raviks.
English: In the body, ridaforolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex'.
Estonian: FKBP-12 külge, moodustades kompleksi, mis blokeerib seejärel mTORi.
English: The active substance in Jenzyl, ridaforolimus, blocks the action of an enzyme called ‘mammalian target of rapamycin' (mTOR), which regulates the growth and division of cells in the body and which has increased activity in patients with sarcoma.
Estonian: Nimetatud ensüüm reguleerib organismis rakkude kasvu ja jagunemist ning selle aktiivsus on sarkoomiga patsientidel suurenenud.
English: 5 x 2 tablets
Estonian: 5 x 2 tabletti
English: Package sizes perforated unit dose blister (PVC/Alu)
Estonian: (PVC/Alu)
English: Medicinal Product no longer authorised
Estonian: Ravimi väljamõeldud nimetus
English: Strength Pharmaceutical Form
Estonian: Tugevus Ravimvorm Manustamisviis Sisepakendi iseloomustus
English: MA (EU) number (Invented) name
Estonian: Ravimi väljamõeldud nimetus
English: This difference was not statistically significant.
Estonian: Erinevus ei olnud statistiliselt oluline.
English: Therefore, these findings are considered to be incidental.
Estonian: Seetõttu peetakse neid leide juhuslikeks.
English: 30 months
Estonian: 30 kuud.
English: The significance for man is unknown.
Estonian: Selle olulisus inimesele ei ole teada.
English: Frequencies are defined as:
Estonian: Esinemissagedused on määratletud järgmiselt:
English: Very rare (<1/10,000) and not known (cannot be estimated from the available data)
Estonian: (<1/10 000) ja teadmata (ei saa hinnata olemasolevate andmete põhjal)
English: He may advise you to stop applying this medicine for a few days (i.e. to have a short rest from treatment).
Estonian: Ta võib anda teile nõu katkestada selle ravimi kasutamine mõneks päevaks (st pidada väike ravipuhkuse periood).
English: Other medicines and Zyclara
Estonian: Muud ravimid ja Zyclara
English: Zyclara is for external use only.
Estonian: Zyclara on ainult välispidiseks kasutamiseks.
English: UNIQUE IDENTIFIER - 2D BARCODE
Estonian: UNIKAALNE IDENTIFIKAATOR - 2D-vöötkood
English: Systemic reactions
Estonian: Süsteemsed reaktsioonid
English: Hands should be washed carefully before and after application of cream.
Estonian: Käsi tuleb pesta hoolikalt nii enne kui pärast kreemi manustamist.
English: • Do not use more cream than your doctor has advised.
Estonian: • Ärge kasutage kreemi rohkem kui arst on määranud.
English: Summary of the safety profile:
Estonian: Ohutusprofiili kokkuvõte:
English: In some individuals a lowering of blood counts was noted (frequency not known).
Estonian: Mõnedel isikutel on täheldatud vererakkude arvu vähenemist (sagedus teadmata).
English: There is also a possibility that existing inflammation may temporarily worsen.
Estonian: Samuti võib olemasolev põletik ajutiselt ägeneda.
English: Mice were maintained for an additional 12 weeks.
Estonian: Hiiri hoiti veel 12 nädalat.
English: Meda AB Pipers väg 2A 170 73 Solna Sweden
Estonian: Meda AB Pipers väg 2A 170 73 Solna Rootsi
English: 61352 Bad Homburg Germany
Estonian: 61352 Bad Homburg Saksamaa
English: If you go outside during the day use sunscreen and wear protective clothing and a wide-brimmed hat.
Estonian: Kui te päevasel ajal käite väljas, kasutage päikesekaitse kreemi ja kandke kaitsvat riietust ning laia äärega kübarat.
English: Date of first authorisation: 23/08/2012 Date of latest renewal: 22/03/2017
Estonian: Müügiloa esmase väljastamise kuupäev: 23/08/2012 Müügiloa viimase uuendamise kuupäev: 22/03/2017
English: Contents of the pack and other information What Zyclara contains
Estonian: Pakendi sisu ja muu teave Mida Zyclara sisaldab
English: Do not use this medicine until your doctor has shown you the right way to use it.
Estonian: Ärge kasutage ravimit kuni arst pole teile näidanud selle korrektset kasutamist.
English: This medicine may reveal and treat actinic keratosis that have not be seen or felt before, and these may later go away.
Estonian: See ravim võib välja tuua ja ravida aktiinilisi keratoose, mida enne pole olnud näha ega tunda, ja need võivad hiljem kaduda.
English: Fertility No clinical data are available, potential risk for human is unknown.
Estonian: Fertiilsus Kliinilisi andmed puuduvad, võimalik risk inimesele ei ole teada.
English: • Do not use sunlamps or tanning-beds, and avoid exposure to sunlight as much as possible during treatment with this medicine.
Estonian: • Ärge kasutage päevavalguslampe ega solaariumit ja hoiduge liigsest päikesekiirgusest ravi ajal selle ravimiga nii palju kui võimalik.
English: Follow-up information suggests that these skin colour changes may be permanent in some patients.
Estonian: Edasised andmed on näidanud, et need muutused naha värvuses võivad olla mõnedel patsientidel püsivad.
English: • Only use the cream externally (on the skin of face or scalp).
Estonian: • Kasutage kreemi ainult välispidiselt (näonahal või peanahal).
English: Dry hands thoroughly and allow the area to dry.
Estonian: Kuivatage käed hoolikalt ning laske pestud piirkonnal kuivada.